Recombinant oncolytic viruses for treatment of metastatic cancers
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Disclosed are recombinant oncolytic viruses that express one or more reovirus fusion-associated small transmembrane FAST) proteins and uses thereof. The oncolytic activity of the recombinant oncolytic viruses expressing FAST proteins can be used to treat primary and metastatic cancers, especially from breast and colon cancers.
Core Innovation
The invention relates to recombinant oncolytic viruses engineered to express reovirus fusion-associated small transmembrane (FAST) proteins. In particular, the recombinant oncolytic virus expresses a p14/p15 combination comprising domain selections from p14 and p15 that specify an ectodomain, a transmembrane domain, and an endodomain arrangement. The approach is directed to treating breast, lung or colon cancer by administering the recombinant oncolytic virus together with pharmaceutically acceptable carriers or excipients.
A FAST protein is presented as a non-enveloped viral membrane fusion protein that enhances cell-cell fusion, syncytia formation, and cytotoxicity in cancer contexts. The content describes recombinant OV platforms in which FAST proteins are expressed, and it connects FAST expression to enhanced pro-inflammatory/immune responses and improved virus transmission within primary and metastatic cancers.
The document further describes experimental support in which a recombinant oncolytic virus expressing FAST proteins is compared to a control expressing GFP. FAST variants comprising p14 or p15, or p14/p15 combinations, are described as increasing spheroid killing and producing delayed tumor growth and prolonged survival, with reduced metastases in breast and colon metastatic models. The document also describes tumor-restricted replication and a preserved biosafety profile, together with immune activation evidenced by splenic T cells and NK cells and CD69+ T cells in tumor and draining lymph nodes, and reports synergy with adoptive immune cell transfer.
Claims Coverage
Inventive features are covered for a method of treating breast, lung or colon cancer using a recombinant oncolytic virus expressing reovirus FAST proteins with specified p14/p15 domain combinations, administered with pharmaceutically acceptable carriers or excipients. The claim set refines treatment to metastatic disease and narrows both FAST composition and oncolytic virus selection, including vesicular stomatitis virus specifically. The inventive features explicitly emphasized across the independent claim and its dependent limitations are: (1) recombinant oncolytic virus expressing specific p14/p15 FAST domain arrangements, (2) administration as a cancer treatment composition with pharmaceutically acceptable carriers or excipients, and (3) metastatic breast/lung/colon cancer targeting and narrowed selections of FAST sources and oncolytic virus types.
Recombinant oncolytic virus expressing p14/p15 FAST combination
A recombinant oncolytic virus that expresses reovirus fusion-associated small transmembrane (FAST) proteins, wherein the FAST protein is a combination of p14/p15 comprising the ectodomain and transmembrane of p14 and the endodomain of p15; the ectodomain of p14, the transmembrane domain and endodomain of p15; or the ectodomain and endodomain of p14 and the transmembrane of p15.
Administration for treating breast, lung or colon cancer with carriers or excipients
Administering to a subject in need thereof a composition consisting of (a) the recombinant oncolytic virus that expresses the FAST proteins and (b) one or more pharmaceutically acceptable carriers or excipients.
Metastatic breast, lung or colon cancer treatment
Treating metastatic breast, lung or colon cancer by the method of administering the FAST-expressing recombinant oncolytic virus composition.
FAST protein sourced from named reovirus p14 and p15
Specifying the FAST protein composition using p14 from reptilian reovirus and/or p15 from baboon reovirus in a p14/p15 combination.
Oncolytic virus selected from specified virus set
Selecting an oncolytic virus from herpesvirus, adenovirus, reovirus, measles virus, Newcastle disease virus, vaccina virus, and vesicular stomatitis virus.
Oncolytic virus as vesicular stomatitis virus
Using an oncolytic virus that is vesicular stomatitis virus.
The claims cover treating breast, lung or colon cancer through administration of a composition containing a recombinant oncolytic virus expressing reovirus FAST proteins with specified p14/p15 domain combinations, formulated with pharmaceutically acceptable carriers or excipients. Dependent limitations further narrow the treated condition to metastatic disease, define FAST composition using named reptilian/baboon reovirus p14/p15 sources, and restrict the oncolytic virus to specified virus types, including vesicular stomatitis virus.
Stated Advantages
Enhanced cell-cell fusion (syncytia formation).
Increased cytotoxicity and spheroid killing.
Delayed tumor growth and prolonged survival.
Reduced metastases.
Maintenance of a tumor-restricted replication/biosafety profile.
Immune activation including splenic T/NK responses and CD69+ T cells in tumor and draining lymph nodes.
Synergistic survival with adoptive immune cell transfer.
Documented Applications
Treating breast, lung or colon cancer by administering a recombinant oncolytic virus that expresses reovirus FAST proteins.
Treating metastatic breast, metastatic lung or metastatic colon cancer with the FAST-expressing recombinant oncolytic virus composition.
Reducing tumor metastasis in breast and colon metastatic models.
Activating innate and adaptive immune responses, including splenic T cells and NK cells, and CD69+ T cells in tumor/draining lymph nodes.
Supporting synergistic outcomes in survival when combined with adoptive immune cell transfer.
Interested in licensing this patent?